A new study found that adjuvant radiotherapy (ART) for high-risk post-prostatectomy patients is associated with superior outcomes compared to early-salvage radiotherapy (ESRT) along three key parameters.
Though the wait is on for the data to mature, apalutamide could lead to survival improvement in a significant number of patients and a major impact on treatment of patients with M0CRPC.
A research team led by noted Cleveland Clinic physician-researcher Nima Sharifi, MD, is honing in on what makes certain men more susceptible to prostate cancer that is likely to progress from hormone-sensitive to castration-resistant.
This study shows that adding androgen deprivation therapy to external beam radiation therapy or brachytherapy for early stage prostate cancer can harm ability to reach orgasm, erection quality and ability to function sexually.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Minority Men’s Health Fair and Minority Men’s Health Center at Cleveland Clinic are “friendly portals of entry” to the healthcare system aimed at reducing disparities for underserved populations.
Cleveland Clinic researchers cover the gamut when it comes to prostate cancer investigation, from elucidating mechanisms behind resistance to therapy to developing more precise diagnostics.
Primary care physicians play a vital role in detecting cancers at earlier stages. Prostate cancer is the most common cancer in the U.S., and screening is still controversial.
Study suggests that novel prostate-specific antigen assay could significantly reduce unnecessary biopsies and help urologists provide men with the information needed to make informed decisions.
Cleveland Clinic research findings suggest that effective steroidal antiandrogens share common metabolic activities and metabolites should be closely examined for effects on tumor survival.
New evidence shows that men on active surveillance of prostate cancer can safely wait at least five years between surveillance biopsies. Study authors hope new findings increase appeal of disease monitoring and reduce patient and provider anxiety.